CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Short interest in Madrigal Pharmaceuticals rose to a four-month high, Ortex data showed, as bearish positions increased ...

Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

Liver fibrosis is a gradually worsening condition marked by excessive collagen buildup resulting from ongoing liver damage.

Discover how metabolic dysfunction-associated steatohepatitis (MASH) damages your liver, its connection to common health ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...

CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite typical Q1 industry ...

Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...